michigan semaglutide gastric stasis class action Unbiased Science teamed up with Your Local Epidemiologist to share the latest research on Ozempic, the medication that has been splashed across social media and news headlines. Let's dig into the science glp-1 gastric stasis lawyer in

My take on the FDA GLP-1 announcement that they intend to Take Action Against Non-FDA-Approved GLP-1 Drugs. Its clearly been sparked by Himss actions

Regulatory History Empowers enforcement record spans nearly a decade across both its 503A and 503B operations: 2017 FDA Warning Letter issued after a 2015 inspection found that Empower produced drug products without valid prescriptions for individually identified patients, and that sterile drug products were prepared under insanitary conditions that put patients at risk 2021 FDA Warning Letter issued to the 503B outsourcing facility after a 2020 inspection found that drug products failed to meet the conditions of Section 503B of the FDCA 2024 FDA Form 483 documented fill weight discrepancies in semaglutide vials, inadequate quality control sampling procedures, and deficiencies in aseptic processing areas April 2025 FDA Warning Letter cited drug products intended or expected to be sterile that were prepared, packed, or held under insanitary conditions

If a provider

However, the small sample with only thirteen patients and a punctual evaluation after using the GLP-1 receptor agonist did not demonstrate significance in the self-administration of the drug and the subjective effect of the drug in patients with cocaine use disorder [99]

[DOI] [PubMed] [Google Scholar] Goldstone AP, Mercer JG, Gunn I, Moar KM, Edwards CM, Rossi M, Howard JK, Rasheed S, Turton MD, Small C, et al